直播时间：2025年5月13日（周二）20:00-21:30
直播平台：
app/kexuewang/liveShare/#/cathay?broadcastId=cdd324dc-c12c-4c58-9f27-d8855865f37c
（科学网APP直播间链接）
北京时间5月13日晚八点，iCANX Youth Talks第97期邀请到了新加坡国家科技研究局高级科学家郭佳怡、北京大学研究员苗蕾担任主讲嘉宾，华南理工大学教授杜步婕、北京大学教授张海霞担任研讨嘉宾，Nextleap.LLC高正宏担任主持人，期待你一起加入这场知识盛宴。
【嘉宾介绍】
郭佳怡
新加坡国家科技研究局
用于创面修复的生物混合两亲性刷状聚合物
【Abstract】
Regenerative medicine-using methods of biological engineering to create the substitutes for the lost or functionally damaged tissues, promote the body s self-repair and regeneration, and bring new hope to diseases such as wound healing, cardiovascular and tumors. At present, the most commonly used clinical methods include autografts, allografts, and synthetic medical materials, however, they heavily rely on the use of biologics such as animal-derived collagen, stem cells or growth factors to promote tissue regeneration towards wound healing. Such techniques often lead to foreign body responses, cost-consuming and extremely demanding logistics and scale-up production. Synthetic polymers are inert, non-toxic and thermally stable. However, they lack bioactivity to facilitate wound healing. Biopolymers such as polysaccharides and collagen have been reported to promote cell adhesion, migration and proliferation. Despite the apparent usefulness of the biopolymers for inducing tissue regeneration, these hygroscopic biomolecules tend to have low stability and lack mechanical strength, making their use in medical devices challenging. Therefore, methods to create biohybrid materials with both bioactivity and stability would be necessary in medical device fabrication.In this talk, I will introduce the modular approach to construct biohybrid brush polymers incorporating functional biomolecules by Ring Opening metathesis Polymerization (ROMP). The synthesized amphiphilic brush polymers are thermally stable to undergo material processing such as 3D-printing and in vitro biocompatible for medical device fabrication. We create couple of devices such as skin patch, foam matrix and non-woven gauze using this biohybrid amphiphilic brush polymers and also demonstrated in vivo healing efficacy on corresponding animal wound models. Particular macromolecules could be designed based on the end functions of devices. This methodology provides a guideline for biohybrid amphiphiles in biomedical applications.
再生医学—利用生物工程方法制造缺失或功能受损组织的替代品，促进人体自我修复和再生，为皮肤、心血管、肿瘤等疾病带来新的希望。目前，临床上最常用的方法包括自体移植、同种异体移植和合成医用材料，然而，这些方法严重依赖于使用动物源性胶原蛋白、干细胞或生长因子等生物制剂来促进组织再生。这些技术通常会导致排异反应，成本高昂，且对物流和规模化生产的要求极高。合成聚合物具有惰性、无毒和热稳定性。然而，它们缺乏促进创面修复的生物活性。据报道，多糖和胶原蛋白等生物聚合物可以促进细胞粘附、迁移和增殖。尽管这些生物聚合物在诱导组织再生方面具有明显的应用价值，但这些吸湿性生物分子往往稳定性低且机械强度低，使其在医疗器械中的应用面临挑战。因此，在医疗器械的打造中，开发兼具生物活性和稳定性的生物混合材料至关重要。本次演讲中，我将介绍一种通过开环复分解聚合（ROMP）引入功能性生物分子来构建生物混合刷状聚合物的模块化方法。合成的两亲性刷状聚合物具有热稳定性，可用于3D打印等材料加工，并且具有体外生物相容性，可用于医疗器械制造。我们利用这种生物混合性两亲性刷状聚合物制造了多种器械，例如皮肤贴片、泡沫基质和无纺布纱布，并在相应的动物伤口模型上证明了其体内愈合功效。我们可以根据器械的最终功能设计特定的大分子。该方法为生物杂化两亲分子在生物医学中的应用提供了指导。
【BIOGRAPHY】
Dr. Guo Jiayi is a Senior Scientist of Agency for Science, Technology and Research (A*STAR) Singapore. She received the B.E. degree in Chemistry from East China University of Science and Technology in 2008, and the Ph.D. degree in Chemistry in 2013, from Nanyang Technological University Singapore. From 2013 to 2014, he was a postdoctoral research fellow in National University of Singapore. She has been a material scientist from 2018 in A*STAR Singapore. Her current research interests include functional polymers for biomedical and environmental fields such as tissue repair matrix, polymer absorbent for CO2 capture, bioplastics, biointerface for wearables sensors. She is the coauthor of more than 30 international peer-reviewed journal papers and patents, including Chemical Communications、Inorganic Chemistry, Dalton Transactions etc. She has rich experience in translational research. One of medical products developed by her is ongoing the clinical trial in Singapore General Hospital. She was awarded by the ideation program from Hong Kong Science Technology Park and entrepreneurship competitions by Zhejiang Province.
郭佳怡博士是新加坡科技研究局（A*STAR）的高级科学家。她于2008年获得华东理工大学化学学士学位，并于2013年获得新加坡南洋理工大学化学博士学位。2013年至2014年，他在新加坡国立大学担任博士后研究员。她自2018年起担任新加坡科技研究局的材料科学家。她目前的研究方向包括功能型聚合物的合成与设计用于生物医学和环境领域，例如组织修复基质、用于二氧化碳捕获的聚合物吸收剂、生物塑料以及用于可穿戴设备传感器的生物界面。她是30多篇国际同行评审期刊论文和专利的共同作者，包括Chemical Communications、Inorganic Chemistry、Dalton Transactions等。她在转化型研究方面拥有丰富的经验。一项由她开发的医疗产品正在新加坡中央医院进行临床试验。郭博士曾获香港科技园创意计划及浙江省创业大赛奖项。
苗蕾
北京大学
功能性天然脂质用于核酸药物的精准递送
【ABSTRACT】
The approval of COVID-19 mRNA vaccines has opened up new possibilities for the clinical application of nucleic acid drugs. However, due to the inherent instability of mRNA and its limited cellular uptake, a highly efficient, safe, and targeted delivery system is urgently needed. Currently, lipid nanoparticles (LNP) are the only FDA-approved nucleic acid drug delivery platform, yet they still face two major challenges: (1) balancing the toxicity and immunogenicity of the delivery carrier; (2) achieving high-efficiency targeted delivery at disease sites.To address these challenges, the current talk will introduce two key strategies: first, modifying lipid structures or formulation compositions to confer LNP with adjuvant or immune-regulating properties, thereby enhancing treatment effectiveness for cancer or chronic inflammation; second, leveraging biomimetic design to enable targeted delivery to T cells and fibroblasts. Through these innovative approaches, we aim to improve the activity and targeting efficiency of LNP, providing greater possibilities for clinical translation.
新冠mRNA疫苗的获批为核酸药物的临床应用开辟了新天地。然而，mRNA药物因稳定性差、入胞受限，亟需高效、安全、靶向的递送系统。目前，脂质纳米颗粒（LNP）是FDA唯一批准的核酸药物递送平台，但其仍面临两大挑战：（1）如何在递送载体的毒性与免疫原性之间取得平衡；（2）如何提升病灶部位的靶向递送效率。针对这些瓶颈，本次报告将探讨两大策略：一是通过调整脂质结构或制剂处方，使LNP具备免疫佐剂或免疫调控功能，以增强抗肿瘤或慢性炎症治疗效果；二是运用天然仿生设计，实现T细胞及成纤维细胞的靶向递送。通过这些创新方案，我们期望提升LNP的活性和靶向性，为其临床转化提供更广阔的可能性。
【BIOGRAPHY】
Lei Miao, Peking University Boya Young Scholar, serves as an Assistant Professor at the Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, and is affiliated with the State Key Laboratory of Natural and Biomimetic Drugs and the Peking University-Yunnan Baiyao International Medical Research Center. She has led several key research projects, including a National Key Program, a Beijing Municipal Science Technology Commission CGT Special Project, and a National Natural Science Foundation General Program. To date, she has published over 40 SCI-indexed papers, including 17 as first or co-first author and 3 as corresponding or co-corresponding author, in prestigious journals such as Nature Biotechnology, Nature Communications, Science Translational Medicine, Cancer Research, ACS Nano, Advanced Functional Materials, Advanced Drug Delivery Reviews, Molecular Cancer, and Journal of Controlled Release, with over 4,000 citations. Her work has been highlighted in top pharmaceutical and chemical review journals. As an inventor, she holds 2 authorized PCT patents, with related intellectual property and research outcomes licensed to U.S. biopharmaceutical companies for the development of anti-tumor vaccines and tumor microenvironment modulators.
苗蕾研究员，北京大学博雅青年学者，北京大学药学院药剂系，天然药物及仿生药物全国重点实验室、北京大学-云南白药国际医学研究中心助理教授，主持北京市重点项目、科技部重点研发项目、北京市科委CGT专项等。截至目前，在该领域发表SCI论文40余篇，其中第一作者（含共同一作）论文17篇，通讯作者（含共同通讯）3篇，包括Nat. Biotechnol.、Nat. Commun.、Sci. Transl. Med.、Cancer Res.、ACS Nano、Adv. Funct. Mater.、Adv. Drug Deliv. Rev.、Mol. Cancer、J. Controlled Release等，论文SCI引用次数4000余次。研究成果被顶级药学及化学综述期刊等重点介绍。作为发明人之一，授权PCT专利2项，相关知识产权及研究成果已转让于美国知名生物制药企业Translate Bio.、初创医药公司OncoTrap和Qualiber用于抗肿瘤疫苗及肿瘤微环境调节剂的研究与开发。
【主持人】
高正宏
Nextleap.LLC
【研讨嘉宾】
杜步婕
华南理工大学
张海霞
北京大学
0 条